AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

NASDAQ:ABCL

AbCellera Biologics Inc.

Last Close

3.10

26/07 20:00

Market Cap

823.35M

Beta: −0.12

Volume Today

692.61K

Avg: 1.63M

PE Ratio

−11.06

PFCF: −20.83